Dec 8 (Reuters) - Biontech22UAy.DE said on Saturday:
BIONTECH AND ONCOC4 ANNOUNCE CLINICALLY MEANINGFUL OVERALL SURVIVAL BENEFIT FOR SELECTIVE TREG MODULATOR GOTISTOBART IN PATIENTS WITH PREVIOUSLY TREATED SQUAMOUS NON-SMALL CELL LUNG CANCER
GOTISTOBART SHOWED A REDUCTION IN THE RISK OF DEATH BY MORE THAN HALF COMPARED TO STANDARD OF CARE CHEMOTHERAPY
GOTISTOBART WAS GRANTED FAST TRACK DESIGNATION BY THE U.S. FOOD AND DRUG ADMINISTRATION (“FDA”)
GRADE ≥3 TREATMENT-RELATED ADVERSE EVENTS (“AES”) WERE REPORTED IN 19/45 (42.2%) PATIENTS IN THE GOTISTOBART TREATMENT ARM VERSUS 20/41 (48.8%) PATIENTS IN DOCETAXEL TREATMENT ARM
Further company coverage: [22UAy.DE]
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))